12590 Glp1 Agonists Role On Prediabetes Reversal, A Meta-analysis

Abstract Disclosure: A. Levy Sitnoveter: None. G. de Azevedo Abrantes: None. G. Carvalhal de Almeida Cordeiro: None. V. Soares Azevedo Junior: None. C. Boccalandro: None. Introduction: The use of glucagon like peptide 1 (GLP-1) agonists to control type two diabetes(T2DM) is well established. However, their role on prediabetes and T2DM prevention is uncertain.This study aimed to assess GLP-1 agonists role in prediabetic patients and whether it can preventor delay new-onset T2DM in this population. Methods: We performed a systematic review and meta-analysis of randomized control trials(RCT) data on the efficacy of GLP-1 agonists in delaying T2DM in prediabetes patients. Studieswithout prediabetic patients or without GLP-1 agonists as intervention were excluded. Tworeviewers collected the data from a total of 1768 studies, of which 791 were duplicated. At the endof the review there were 41 conflicts, which were analyzed by a third reviewer. After the completereading of 13 studies, 9 were excluded. Results: We included 4 RCT comprising 1717 patients (72% women from baseline). We included4 RCT comprising 1717 patients (72% women from baseline). All patients were obese, and themean follow-up duration was 30 weeks. Overall patient's taking GLP-1 agonists showed asignificant reversal of prediabetes by achieving normoglycemia (MD +5.99 [CI +4.41, 8.12]). Thestudies displayed anConclusion: GLP-1 Agonists appear to be safe and effective in lowering the progression to T2DMin patients with prediabetes and obesity. Further trials should explore the GLP-1 agonist effect onprediabetes beyond the obese population.GLP-1 agonists appeared to be safe and effective in lowering the progression to T2DM inpatients with prediabetes. Presentation: 6/1/2024